ArticleFrontiers in medicine2023
Friedewald formula may be used to calculate non-HDL-C from LDL-C and TG.
Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Atherogenic lipid indices and diabetic retinopathy in type 2 diabetes: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Sex-Specific Prevalence and Associated Factors of Dyslipidemia in Korean Adults: A Cross-Sectional Study.Health science reports · 2026Article
- Cardiovascular Health Characterization Using Life's Essential 8 Score in Perimenopausal Women: An Analysis of the National Health and Nutritional Examination Survey.Journal of the American Heart Association · 2026Article
- Creatinine-to-body weight ratio as an independent predictor of hepatic steatosis severity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.BMC gastroenterology · 2026Article
- Insulin Resistance in Systemic Sclerosis: Decoding Its Association with Severe Clinical Phenotype.Journal of clinical medicine · 2026Article
- The Relationship Between Visceral Fat Obesity and the Atherogenic Combined Index in Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Cranberry improves metabolic syndrome-related organ dysfunction in rats by modulating AMPK/SREBP1, ROCK1 and TGF-β1.Scientific reports · 2025Article
- Effects of Pomegranate Juice on Androgen Levels, Inflammation and Lipid Profile in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- The Intersection BetweenTropical medicine and infectious disease · 2025Article
- Effects of a 26 week multicomponent exercise program on cardiovascular and lipid profiles in premenopausal and postmenopausal women.Scientific reports · 2025Article
- Nanotechnology and Artificial Intelligence in Dyslipidemia Management-Cardiovascular Disease: Advances, Challenges, and Future Perspectives.Journal of clinical medicine · 2025Review
- Impact of Graves' hyperthyroidism treatment on lipid profiles and cholesterol dynamics: a prospective observational study.Therapeutic advances in endocrinology and metabolism · 2025Article
- Exploring the bidirectional link between erectile dysfunction and 10-year cardiovascular risk in men with diabetes and hypertension.Scientific reports · 2024Observational
- The correlation between liver fibrosis and the 10-year estimated risk of cardiovascular disease in adults with metabolic-associated fatty liver disease: A cross-sectional study in Vietnam.Health science reports · 2024Article
- [Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Friedewald formula (FF) was originally designed 50 years ago and has been in use to this day despite better methods for estimating LDL cholesterol (LDL-C). Its success was mainly due to its simplicity. Nowadays most laboratories determine or can determine LDL-C by the direct method. The SCORE2 tables, recommended by the European Society of Cardiology, are based on non-HDL cholesterol (non-HDL-C). To calculate its value, one needs to know the values of total cholesterol (TC) and HDL-C. The presented idea is to use the FF to calculate non-HDL-C based on the values of LDL-C and TG instead of TC and HDL-C. Methods and findings: Based on database of 26,914 laboratory results, covering the complete lipid panel, the error regarding non-HDL-C values calculated in both ways (recommended and proposed) was determined. The average error in the LDL-C value calculated with the FF compared to the LDL-C value measured in the laboratory is 9.77%, while for non-HDL-C the error between the calculated and laboratory-determined value amounts to 8.88%. The proposed transformation of the FF also yields a much lower percentage of error calculations. Both LDL-C and non-HDL-C (calculated) in our material are strongly correlated with LDL-C and non-HDL-C (measured) values of Conclusion: Non-HDL-C may be calculated based on the values of LDL-C and TG (without the need to determine the levels of TC and HDL-C). The proposed calculation may greatly reduce the cost of testing, given the price of a complete lipid profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.